Literature DB >> 19501406

Blood-assisted internal limiting membrane peeling for macular hole repair.

Chi-Chun Lai1, Yih-Shiou Hwang, Laura Liu, Kuan-Jen Chen, Wei-Chi Wu, Lan-Hsin Chuang, Jane Zea-Chin Kuo, Tun-Lu Chen.   

Abstract

PURPOSE: To evaluate the efficacy of autologous heparinized whole blood in assisting internal limiting membrane (ILM) peeling by coating the ILM for macular hole (MH) repair.
DESIGN: Prospective, interventional case series. PARTICIPANTS: Twenty-nine patients (32 eyes) who underwent blood-assisted ILM peeling for MH repair.
METHODS: Patients in whom stage 2-4 idiopathic MHs had developed and who desired surgery were enrolled in this study. After core vitrectomy, autologous heparinized whole blood was applied to cover the macula and to coat the surface of the macular area in the fluid-filled vitreous cavity. The redundant blood was removed and only a very thin film of blood was left on the macular area. The blood-coated ILM was removed by forceps in a circular fashion. To confirm the removed membrane was the ILM, the first 10 specimens were examined by electron microscopy (EM). MAIN OUTCOME MEASURES: The MH closure rate, the interval mean visual acuity (before and after surgery), retinal changes, and the EM results of the ILM specimens.
RESULTS: All 32 eyes in 29 patients completed 12 months of follow-up. The ILM were coated by autologous heparinized whole blood, removed without difficulty, and confirmed by EM. The whole blood highlighted the contrast of the coated and noncoated areas during the ILM peeling procedure. The MHs were closed in all surgical eyes with a single surgery (100%). Compared with study entry, the mean logMAR best-corrected visual acuity 12 months after surgery improved significantly (1.02 and 0.53, respectively; P<0.001). At 12 months of follow-up, 31 eyes (96.9%) had stable or improved vision. No toxic fundus changes were observed during follow-up.
CONCLUSIONS: Autologous heparinized whole blood coated the ILM and facilitated visibility during ILM peeling. Autologous heparinized whole blood is a cost-effective and useful tool for assisting MH surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19501406     DOI: 10.1016/j.ophtha.2009.02.025

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Comparing the inverted internal limiting membrane flap with autologous blood technique to internal limiting membrane insertion for the repair of refractory macular hole.

Authors:  Zhixiang Hu; Haishuang Lin; Qihua Liang; Ronghan Wu
Journal:  Int Ophthalmol       Date:  2019-08-28       Impact factor: 2.031

2.  Internal limiting membrane dragging and peeling: a modified technique for macular holes closure surgery.

Authors:  Jie Peng; Li-Hua Zhang; Chun-Li Chen; Jing-Jing Liu; Xiu-Yu Zhu; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

3.  Autologous neurosensory retinal transplantation for large refractory idiopathic macular hole.

Authors:  Kenan Sonmez
Journal:  Int Ophthalmol       Date:  2021-01-21       Impact factor: 2.031

4.  The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Authors:  Lan-Hsin Chuang; Yih-Shiou Hwang; Nan-Kai Wang; Yen-Po Chen; Laura Liu; Ling Yeung; Kuan-Jen Chen; Tun-Lu Chen; Wei-Chi Wu; Chi-Chun Lai
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-20       Impact factor: 2.671

5.  Management of refractory macular hole with blood and gas-assisted autologous neurosensory retinal free flap transplantation: a case report.

Authors:  Pei-Kang Liu; Yo-Chen Chang; Wen-Chuan Wu
Journal:  BMC Ophthalmol       Date:  2018-09-03       Impact factor: 2.209

Review 6.  Spotlight on the Internal Limiting Membrane Technique for Macular Holes: Current Perspectives.

Authors:  Tomaso Caporossi; Matteo Mario Carlà; Gloria Gambini; Umberto De Vico; Antonio Baldascino; Stanislao Rizzo
Journal:  Clin Ophthalmol       Date:  2022-04-06

7.  The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial.

Authors:  Shafi Balal; Arit Udoh; Yannis Pappas; Erica Cook; Garry Barton; Ali Hassan; Karen Hayden; Rupert Richard Alexander Bourne; Sajjad Ahmad; Shahina Pardhan; Michael Harrison; Benjamin Sharma; Mohammad Wasil; Anant Sharma
Journal:  BMJ Open       Date:  2018-10-31       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.